KBY Biotech Indexv0.0.34
Search
← Pipeline|NAT-IIT-794

NAT-IIT-794

Approved
By Natl Cancer Ctr Singapore
Source: Trial-derived·Trials: 1
Modality
Nanobody
MOA
TROP-2 ADC
Target
Cl18.2
Pathway
Proteasome
CML
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
~Jul 2019
→ ~Oct 2020
Phase 3
~Jan 2021
→ ~Apr 2022
NDA/BLA
~Jul 2022
→ ~Oct 2023
Approved
Jan 2024
→ Jun 2028
ApprovedCurrent
NCT03163565
365 pts·CML
2024-01→2028-06·Terminated
365 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-06-082.2y awayPh3 Readout· CML
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Approved
Termina…
Catalysts
Ph3 Readout
2028-06-08 · 2.2y away
CML
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03163565ApprovedCMLTerminated365FEV1
Competitors (10)
DrugCompanyPhaseTargetMOA
MavutenlimabJohnson & JohnsonPhase 3Cl18.2Menini
JNJ-2735Johnson & JohnsonPhase 2/3Cl18.2MALT1i
RibosacituzumabRocheApprovedCl18.2KIF18Ai
AdagrazumabNovartisPhase 2/3Cl18.2EZH2i
ZorimavacamtenBristol-Myers SquibbPreclinicalCl18.2CDK4/6i
BAY-6520BayerPhase 2AHRTROP-2 ADC
DoxafotisoranDaiichi SankyoPhase 1Cl18.2WEE1i
BemazumabRegeneronPhase 1VEGFTROP-2 ADC
GMA-5010GenmabPhase 3JAK2TROP-2 ADC
INC-1582IncytePhase 1/2APOC3TROP-2 ADC